Meeting
2020 ASCO Virtual Scientific Program
Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.
Authors
Martin Hutchings
Rigshospitalet, Copenhagen, Denmark
Martin Hutchings , Pieternella Lugtenburg , Rogier Mous , Michael Roost Clausen , Martine Chamuleau , Kim Linton , Simon Rule , Juanita Suzanne Lopez , Roberto S Oliveri , Dena DeMarco , Brian Elliott , Peter Johnson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03625037
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8009)
DOI
10.1200/JCO.2020.38.15_suppl.8009
Abstract #
8009
Poster Bd #
342
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.
First Author: Yasmin Karimi
Poster
2022 ASCO Annual Meeting
Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.
First Author: Lorenzo Falchi
Poster
2021 ASCO Annual Meeting
Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.
First Author: Michael Roost Clausen
Poster
2016 ASCO Annual Meeting
A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs).
First Author: Philippe Armand